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Abstract
Inflammatory tolerance is a crucial mechanism that limits inflammatory responses in order to avoid prolonged inflammation
that may damage the host. Evidence that chronic inflammation contributes to the neuropathology of prevalent
neurodegenerative and psychiatric diseases suggests that inflammatory tolerance mechanisms are often inadequate to
control detrimental inflammation in the central nervous system. Thus, identifying mechanisms that regulate
neuroinflammatory tolerance may reveal opportunities for bolstering tolerance to reduce chronic inflammation in these
diseases. Examination of tolerance after repeated lipopolysaccharide (LPS) treatment of mouse primary astrocytes
demonstrated that histone deacetylase (HDAC) activity promoted tolerance, opposite to the action of glycogen synthase
kinase-3 (GSK3), which counteracts tolerance. HDAC6 in particular was found to be critical for tolerance induction, as its
deacetylation of acetyl-tubulin was increased during LPS tolerance, this was enhanced by inhibition of GSK3, and the
HDAC6 inhibitor tubacin completely blocked tolerance and the promotion of tolerance by inhibition of GSK3. These results
reveal opposing interactions between HDAC6 and GSK3 in regulating tolerance, and indicate that shifting the balance
between these two opposing forces on inflammatory tolerance can obliterate or enhance tolerance to LPS in astrocytes.
Citation: Beurel E (2011) HDAC6 Regulates LPS-Tolerance in Astrocytes. PLoS ONE 6(10): e25804. doi:10.1371/journal.pone.0025804
Editor: Guenter Schneider, Technische Universita ¨tM u ¨nchen, Germany
Received June 23, 2011; Accepted September 11, 2011; Published October 12, 2011
Copyright:  2011 Ele ´onore Beurel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the National Instute of Mental Health (NIMH), National Institutes of Health (NIH)(MH090236 and MH038752).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: eleonore_beurel@hotmail.fr
Introduction
The inflammation response is a vital reaction to cell damage,
disease, or infection, and includes intrinsic down-regulatory
mechanisms that are crucial for limiting damage to the host [1].
These inhibitory processes include tolerance, the cumulative
outcome of multiple down-regulating mechanisms that is charac-
terized as reduced responses to repeated or extended exposure to
an inflammatory stimulus, such as lipopolysaccharide (LPS) [2].
Tolerance mechanisms appear to be impaired relatively frequently
in the central nervous system (CNS) because many neurological
and psychiatric diseases are associated with excessive inflamma-
tion, exemplified by elevated levels of the pro-inflammatory
cytokine interleukin-6 (IL-6) [3,4,5,6,7]. This dysregulated inhib-
itory control of neuroinflammation can promote disease suscep-
tibility, exacerbate neuropathology, and hinder responses to
therapeutic interventions. Thus, identification of tolerance mech-
anisms amenable to intervention may provide new strategies for
controlling neuroinflammation to bolster therapeutic responses.
Neuroinflammation is mediated by the CNS resident immune
cells, astrocytes and microglia [8,9]. Although both cell types
contribute to cytokine production in the CNS, the immune
properties of astrocytes differ from those of microglia, including
characteristics of inflammatory tolerance that contributes to
limiting neuroinflammation [10]. Microglia, which share a
common myeloid lineage with macrophages, display complete
tolerance in the production of IL-6 in response to repeated
stimulation with LPS [10], as do macrophages [11], so a second
exposure to LPS fails to elicit IL-6 production by these cells. In
contrast, astrocytes display a characteristic of semi-tolerance in
response to repeated exposure to LPS, with IL-6 production
diminished but not eliminated by pre-exposure to LPS [10]. In
astrocytes, inflammatory tolerance is enhanced by inhibition of
glycogen synthase kinase-3 (GSK3) [10], whereas in macrophages
inflammatory tolerance is counteracted by inhibition of histone
deacetylases (HDACs) [11]. These opposing regulatory influences
of GSK3 and HDACs on inflammatory tolerance raised the
possibility of interactions between GSK3 and HDACs in the
modulation of tolerance. The class IIb HDAC, HDAC6 [12], has
previously been shown to modify the regulation by GSK3 of b-
catenin [13] and tau [14]. HDAC6 differs from most other
HDACs in that HDAC6 is predominantly cytosolic and acetyl-
tubulin is a major substrate [12]. These relationships prompted
this study to test if HDAC6 is involved in regulating inflammatory
tolerance, and the modulatory action of GSK3, on tolerance in
astrocytes. The results demonstrate that HDAC6 is activated
during LPS-tolerance, and inhibition of HDAC6 blocks LPS-
induced tolerance of IL-6 production and the ability of GSK3
inhibitors to promote tolerance in astrocytes.
Methods
Ethics Statement
All mice were housed and treated in accordance with National
Institutes of Health guidelines and procedures with mice were
approved by the University of Alabama at Birmingham Institu-
tional Animal Care and Use Committee (APN100508040).
Reagents
Sources of chemicals were TDZD-8 (Calbiochem), sodium
butyrate, valproic acid, trichostatin A (TSA), anacardic acid,
59azacytidine, LiCl (Sigma), pargyline (Alexis), tubacin (a gift from
Dr. Mazitschek) and CT99021 (University of Dundee, UK).
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Primary glia were prepared from the cerebral cortex of 1 day
old C57Bl/6 mice or GSK3 knockin mice as described [15], and
cultured in DMEM/F12 medium supplemented with 10% FBS,
0.3% glucose, 2 mM L-glutamine, 10 U/mL penicillin and
10 mg/mL streptomycin. For separation of astrocytes and
microglia, after 10 days of culture the cells were shaken (30 h;
250 rpm), resulting in .99% pure astrocytes as determined by
immunostaining with the astrocyte marker glial fibrillary acidic
protein (GFAP). Astrocytes were cultured for up to four weeks for
experiments, were trypsinized only twice, and were used at
approximately 100% confluency in all experiments. Astrocytes
were plated in different sized plate for experiments. After the first
hour of shaking, the medium containing microglia cells was
collected and microglia were cultured in the same medium as
astrocytes with approximately 10
6 cells per well in 24 well plates,
and microglia were used in experiments within one week of
isolation. RAW264.7 cells were cultured as described previously
[16]. Bone marrow cells were isolated from the tibia of C57Bl/6
mice, and cultured for 6 days in the presence of M-CSF in RPMI
1640 medium supplemented with 10% FBS, 100 IU/mL
penicillin, 100 mg/mL streptomycin, 16nonessential amino acids,
1 mM sodium pyruvate, 2.5 mM b-mercaptoethanol and 2 mM L-
glutamine, to obtain after 6 days of culture bone marrow-derived
macrophages (BMM). Cells were left untreated (naive, 0) or
stimulated with 100 ng/mL LPS for 24 h (to establish LPS-
tolerance) in medium supplemented with 10% FBS, washed twice
with warm medium, and given fresh media with all supplements
(0/0) or with all supplements and 10 ng/mL LPS (0/LPS, LPS/
LPS) for 1 h or 24 h. Where indicated, cells were treated with
10 mM CT99021, TDZD-8, 59 azacytidine (AZA), anacardic acid
(AA), or tubacin, 3 mM pargyline, 20 mM LiCl, 5 mM sodium
butyrate (NaBu), 5 mM valproic acid (VPA), or 50 nM TSA.
ELISA
IL-6 levels were measured by ELISA according to the
manufacturer’s instructions (eBioscience).
Immunoblotting
Western blots were carried out as described previously [17]
using antibodies to GSK3a/b (Millipore), GSK3b (BD Transduc-
tion), acetyl-tubulin, a-tubulin, HDAC6 and b-actin (Sigma).
HDAC6 activity
HDAC6 activity was measured using a colorimetric HDAC6
assay kit (Abcam) according to the manufacturer’s protocol.
Cytosolic extracts were obtained using the nuclear kit extraction
from Active Motif according to the manufacturer’s protocol.
tubacin-insensitive activity was subtracted from total activity to
obtain the activity of HDAC6.
Statistical analysis
Statistical significance between groups was evaluated by
ANOVA with a post-hoc Dunnett’s multiple comparison test
where appropriate or by Student’s t-test.
Results
HDAC inhibitors counteract LPS-induced semi-tolerance
of IL-6 production in astrocytes
Tolerance to LPS in macrophages was reported to be blocked
by HDAC inhibitors [11]. Therefore, we tested if the HDAC
inhibitors sodium butyrate, trichostatin A (TSA), and valproic acid
blocked the development of semi-tolerance to LPS-stimulated IL-6
production and its facilitation by GSK3 inhibitors in astrocytes. As
described previously [10], tolerance is determined by measuring
the difference in IL-6 production by cells pre-exposed, or not, to
LPS (Fig. 1A). Microglia preincubated with LPS produced little
IL-6 upon restimulation with LPS, demonstrating full tolerance to
LPS, which was not significantly modified by GSK3 inhibitors
(Fig. 1B). Astrocytes preincubated with LPS produced ,50% less
IL-6 upon restimulation with LPS than did astrocytes not pre-
exposed to LPS (Fig. 1C), demonstrating a phenotype of semi-
tolerance. Astrocyte semi-tolerance to LPS was converted to more
complete tolerance by co-treatment during the first exposure to
LPS with GSK3 inhibitors, including lithium [18,19], CT99021
[20] and TDZD-8 [21], as reported previously [10].
Opposite to the effects of GSK3 inhibitors, treatment with the
HDAC inhibitors sodium butyrate (Fig. 1D) or TSA (Fig. 1E)
during the first LPS stimulation of astrocytes completely blocked
the induction of semi-tolerance in astrocytes. This demonstrates a
requirement in astrocytes for active HDACs for the development
of semi-tolerance to LPS in IL-6 production. Blockade of tolerance
to LPS-induced IL-6 production by TSA in astrocytes matches the
reported inhibition of tolerance by TSA in bone marrow-derived
macrophages [11]. Examination of the effects of HDAC inhibitors
on tolerance in primary microglia was not possible because the
HDAC inhibitors induced rapid cell death in microglia, as
reported previously [22].
To test whether inhibition of HDACs or GSK3 was dominant
in regulating tolerance to LPS, astrocytes were treated with both
types of inhibitors. This revealed that the promotion of tolerance
induced by treatment with the GSK3 inhibitor lithium during the
initial LPS stimulation was blocked by treatment with sodium
butyrate (Fig. 1D) or TSA (Fig. 1E). Thus, active HDACs are
required in order for inhibition of GSK3 to promote LPS-
tolerance, as depicted in the scheme shown in Fig. 1F. In
summary, these findings demonstrate that HDAC inhibitors
counteract tolerance whereas GSK3 inhibitors promote tolerance
[10], demonstrating the opposing actions of GSK3 (counteracting
tolerance) and of HDACs (promotion of tolerance) in LPS-induced
semi-tolerance in astrocytes.
Unlike HDAC inhibitors, LPS-tolerance was unaffected by
pretreatment with pargyline, an inhibitor of H3 demethylase
LSD1 (Fig. 2A), 5’azacytidine, a DNA methylase inhibitor
(Fig. 2B), or the HAT inhibitor anacardic acid (Fig. 2C),
emphasizing the selective involvement of HDACs in the astrocytic
LPS-semi-tolerance.
HDAC6 promotes LPS-tolerance
In contrast to sodium butyrate and TSA, treatment of astrocytes
with the HDAC inhibitor valproic acid did not block the
promotion by lithium of LPS-tolerance in IL-6 production
(Fig. 3A). Valproic acid inhibits the same HDACs as sodium
butyrate and TSA except for HDAC6 and HDAC10, which are
not inhibited by valproic acid [23]. The capacity of lithium to
promote LPS-tolerance in the presence of valproic acid but not
with sodium butyrate or TSA suggested that this action of lithium
may involve HDAC6 or HDAC10, indicating that these may be a
target of GSK3 to counteract LPS-tolerance.
To specifically examine the role of HDAC6 in regulating
tolerance, we tested if inhibiting HDAC6 with tubacin, a small
molecule selective inhibitor of HDAC6 [24], was sufficient to
promote LPS-tolerance. Acetylated-tubulin is a substrate of
HDAC6, so increased acetyl-tubulin is a marker of HDAC6
inhibition [24,25]. Treatment with tubacin markedly increased
acetylated-tubulin (Fig. 3B) and completely blocked LPS-tolerance
HDAC6 Regulates Tolerance
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25804of IL-6 production in astrocytes (Fig. 3C), demonstrating that
HDAC6 is required for LPS-tolerance in astrocytes. Tubacin also
increased acetylated-tubulin in microglia (Fig. 3B) and appeared to
counteract LPS-tolerance in microglia (Fig. 3D). However, in
microglia pretreatment with tubacin alone induced a significant
reduction of IL-6 production after one stimulation with LPS,
suggesting an important role of HDAC6 in the microglial response
to LPS, which limits conclusions about the role of HDAC6 in
inflammatory tolerance in microglia. That HDAC6 is particularly
important in the induction of LPS-induced semi-tolerance in
Figure 1. LPS-tolerance is blocked by HDAC inhibitors. A, Scheme of the LPS tolerance paradigm. Mouse primary microglia (B) or astrocytes (C)
were pretreated where indicated with 100 ng/mL LPS (L) or no LPS (0) and the GSK3 inhibitors LiCl (20 mM), CT99021 (10 mM) or TDZD-8 (10 mM), for
24 h and restimulated with 10 ng/mL LPS for 24 h. Media were analyzed for IL-6 by ELISA. Data represent mean 6 SEM, n=3–6, *p,0.05 (ANOVA) in
(B) compared with 0/L treatments, and in (C) compared with L/L in the absence of a GSK3 inhibitor. D–E, Mouse primary astrocytes were pretreated
where indicated with 100 ng/mL LPS or no LPS (0) and the HDAC inhibitors 5 mM sodium butyrate (NaBu) (D), or 50 nM TSA (E), with or without
20 mM LiCl, for 24 h and restimulated with 10 ng/mL LPS for 24 h. Media were analyzed for IL-6 by ELISA. Data are representative of 3–4 experiments.
F, Scheme of the opposing actions of GSK3 and HDAC in LPS tolerance.
doi:10.1371/journal.pone.0025804.g001
Figure 2. LPS-tolerance is not blocked by inhibitors of DNA methylase, H3 methylase or HATs in astrocytes. Astrocytes were pretreated
where indicated with 100 ng/mL LPS or no LPS (0) and A,3mM pargyline (Parg), B,1 0mM5 9azacytidine (AZA) or C,1 0mM anacardic acid (AA) for 24 h
and restimulated with 10 ng/mL LPS for 24 h. Supernatants were analyzed for IL-6 by ELISA (n=3–4). Values represent mean 6 SEM.
doi:10.1371/journal.pone.0025804.g002
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LPS-tolerance was associated with a 50% decrease in acetyl-
tubulin in LPS-tolerant astrocytes compared with a single
exposure to LPS (Figs. 3E and 4A), indicative of activation of
the HDAC6-mediated deacetylation of acetyl-tubulin during
tolerance. However, this was not due to a generalized increase
in HDAC6 activity, as HDAC6 activity in whole cell lysates (not
shown) and in cytosolic fractions (Fig. 3F) was equivalent in
astrocytes treated with LPS once or for two sequential periods.
Treatment with TSA, but not valproic acid, also blocked the
decrease in acetyl-tubulin caused by the LPS/LPS treatment
(Fig. 3E), matching their differential modulatory effects on semi-
tolerance in IL-6 production and the inhibition of HDAC6 by
TSA but not by valproic acid [23].
LPS-stimulated TLR4 results in changes in the production of
multiple cytokines that could contribute to changes in HDAC6.
To begin to test if inflammatory cytokines may mediate the
modulation of HDAC6 following LPS treatment, we tested in
Figure 3. HDAC6 inhibition counteracts tolerance. A, Mouse primary astrocytes were pretreated where indicated with 100 ng/mL LPS or no
LPS (0) and the HDAC inhibitor 5 mM valproic acid (VPA), with or without 20 mM LiCl, for 24 h and restimulated with 10 ng/mL LPS for 24 h. Media
were analyzed for IL-6 by ELISA. Data are representative of 3–4 experiments, *p,0.05, ANOVA. B, Mouse primary astrocytes (top panel) or microglia
(bottom panel) were pretreated where indicated with 100 ng/mL LPS or no LPS (0) with or without the HDAC6 inhibitor tubacin (10 mM) for 24 h and
restimulated with 10 ng/mL LPS for 1 h. Cell extracts were immunoblotted for acetyl-a-tubulin (Ac Tubulin), and re-blotted for total a-tubulin (n=3).
Mouse primary astrocytes (C) or microglia (D) were pretreated where indicated with 100 ng/mL LPS or no LPS (0) and the HDAC6 inhibitor tubacin
(10 mM) for 24 h and restimulated with 10 ng/mL LPS for 24 h. Media were analyzed for IL-6 by ELISA. Data represent mean 6 SEM, n=6, *p,0.05,
ANOVA. E, Mouse primary astrocytes were pretreated where indicated with 100 ng/mL LPS or no LPS (0) and the HDAC inhibitors 5 mM valproic acid
(VPA) or 50 nM TSA for 24 h and restimulated with 10 ng/mL LPS for 1 h. Cell extracts from astrocytes were immunoblotted for acetyl-a-tubulin, and
re-blotted for total a-tubulin (n=4). F, Mouse primary astrocytes were pretreated with 100 ng/mL LPS or no LPS (0) for 24 h and restimulated with
10 ng/mL LPS for 1 h. HDAC6 activity was measured in cytosolic extracts. The histogram represents mean 6 SEM of the tubacin-inhibited HDAC
activity. G, Mouse primary astrocytes were treated with 10 ng/mL of either IL-6, IL-12, TNFa, or IFNc for 1 or 24 h. Cell extracts from astrocytes were
immunoblotted for acetyl-a-tubulin, and re-blotted for total a-tubulin.
doi:10.1371/journal.pone.0025804.g003
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altered the activity of HDAC6 as indicated by changes in acetyl-
tubulin. Treatment of primary astrocytes for 1 or 24 hr with
10 ng/mL of either IL-6, IL-12, TNFa, or IFNc did not alter
acetylated tubulin (Fig. 3G), indicating that signaling mechanisms
other than these cytokines mediate the change in HDAC6 elicited
by LPS treatment.
GSK3 counteracts tolerance through inhibition of HDAC6
Inhibition of GSK3 with lithium, which promotes tolerance,
decreased acetyl-tubulin levels in conjunction with promoting
LPS-induced tolerance, whereas treatment with lithium alone in
the absence of LPS did not alter acetyl-tubulin (Fig. 4A). GSK3
inhibition in conjunction with LPS/LPS treatments also decreased
acetyl-tubulin in primary bone marrow-derived macrophages
(Fig. 4B) and RAW264.7 cells (Fig. 4C), demonstrating this is
not a cell type-dependent action. Examination of HDAC6 activity
in cytosolic extracts (Fig. 4D) also demonstrated a significant
increase in HDAC6 activity in the presence of lithium during LPS-
induced tolerance, indicating that GSK3 decreases HDAC6
activity during LPS tolerance.
Oppositely to examining the effects of GSK3 inhibitors on semi-
tolerance in astrocytes, the effects of increased GSK3 activity were
assessed by using astrocytes prepared from GSK3 knockin mice.
This tactic was used instead of overexpressing GSK3 because
previous studies have shown that overexpression of GSK3b in
astrocytes causes apoptosis [26]. The two isoforms of GSK3 are
predominantly regulated by inhibitory phosphorylation on serine-
21-GSK3a and serine-9-GSK3b [27]. Examination of the effects
of constitutively maximal GSK3 activity can be studied using
homozygous GSK3a
21A/21A/b
9A/9A knockin mice, where the
regulatory serines of both GSK3 isoforms are mutated to alanines
[28], which maintain GSK3 maximally active, but within the
physiological range. In astrocytes from GSK3 knockin mice, there
Figure 4. Lithium increases HDAC6 activity to promote tolerance. A, Mouse primary astrocytes were pretreated where indicated with
100 ng/mL LPS or no LPS (0) and the GSK3 inhibitor LiCl (20 mM) for 24 h (left panel) or the indicated time (right panel) and restimulated with 10 ng/
mL LPS for 1 h (left panel) or LiCl (20 mM) for 24 h or the indicated time (right panel). Cell extracts were immunoblotted for acetyl-a-tubulin, and re-
blotted for total a-tubulin. The ratio of acetylated-tubulin to total a-tubulin was quantitated. Histograms represent mean 6 SEM, n=5, *p,0.05,
ANOVA compared to results in cells not treated with lithium. Mouse primary BMM (B) or RAW267.1 cells (C) were pretreated where indicated with
100 ng/mL LPS or no LPS (0) and the GSK3 inhibitor LiCl (20 mM) for 24 h and restimulated with 10 ng/mL LPS for 1 h. Cell extracts were
immunoblotted for acetyl-a-tubulin, and re-blotted for total a-tubulin (n=3). D, Mouse primary astrocytes were pretreated where indicated with
100 ng/mL LPS or no LPS (0) and the GSK3 inhibitor LiCl (20 mM) for 24 h and restimulated with 10 ng/mL LPS for 1 h. HDAC6 activity was measured
in cytosolic extracts. The histogram represents mean 6 SEM of the tubacin-inhibited HDAC activity, n=3, *p,0.05, ANOVA. E, Mouse primary
astrocytes isolated from GSK3 knockin mice were pretreated where indicated with 100 ng/mL LPS or no LPS (0) for 24 h and restimulated with 10 ng/
mL LPS for 1 h. Cell extracts were immunoblotted for acetyl-a-tubulin, and re-blotted for total a-tubulin. The ratio of acetylated-tubulin to total
tubulin was quantitated (mean 6 SEM, n=4, *p,0.05, ANOVA).
doi:10.1371/journal.pone.0025804.g004
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was no decrease in acetyl-tubulin after LPS/LPS treatment, but
rather an increase, in astrocytes from GSK3 knockin mice
(Fig. 4E). Thus, the blockade of LPS-induced semi-tolerance in
astrocytes expressing fully active GSK3 was associated with a
block in LPS-induced HDAC6 activation. These results demon-
strate that LPS-tolerance requires inhibition of GSK3 to reduce
GSK3-dependent inhibition of HDAC6.
GSK3 associates with HDAC6
To test if HDAC6 inhibition by GSK3 may be a direct effect,
co-immunoprecipitation was used to test if the proteins were
associated. Both GSK3a and GSK3b co-immunoprecipitated with
HDAC6 (Fig. 5A). Furthermore, the association of HDAC6 with
GSK3 was significantly decreased in tolerant LPS/LPS-stimulated
astrocytes, demonstrating that tolerance is associated with
dissociation of inhibitory GSK3 from HDAC6 to permit HDAC6
to promote tolerance.
To analyze if GSK3 by inhibiting HDAC6 modulates IL-6
production, we examined the effects of tubacin on lithium
promotion of LPS-tolerance in IL-6 production. The promotion
by lithium of LPS-tolerance in IL-6 production was abolished in
the presence of the HDAC6 inhibitor, tubacin. To confirm that
tubacin blocks the effects of lithium of HDAC6 activity, we also
examined acetylated-tubulin levels and found that tubacin
prevented the reduction by lithium of tubulin acetylation. Taken
together, these results demonstrated that HDAC6 activity is
increased by LPS-tolerance and this is counteracted by active
GSK3.
Discussion
Inflammation in the CNS can have particularly detrimental
consequences if it damages neurons, which cannot be replaced.
Since markers of excessive neuroinflammation have been
identified in association with many neurodegenerative and
psychiatric diseases, it is important to devise interventions that
can control neuroinflammation [4,5,6]. One potential method to
protect the CNS from irreversible damage induced by inflamma-
tion is to bolster endogenous mechanisms of inflammatory
tolerance, which is characterized by the dampening of inflamma-
tory responses to repeated inflammatory stimuli. Although
microglia appear to exhibit full inflammatory tolerance to LPS
similar to the closely related peripheral macrophages, astrocytes
exhibit less complete tolerance, providing an opportunity to
identify interventions capable of bolstering the development of
tolerance. However, little is known about inflammatory tolerance
mechanisms in the CNS, in contrast to the periphery where LPS-
tolerance has been well-characterized. Tolerance mechanisms
identified in the periphery include the induction of anti-
inflammatory cytokines (e.g., IL-10, TGFb) to counteract the
inflammatory response [29,30,31,32,33] and down-regulation of
the LPS-responsive TLR4 signaling pathway [34], including
internalization of TLR4 from the cell surface [35], reduced
activation of the inflammatory cytokine-inducing transcription
factor NF-kB [36,37], and chromatin modifications leading to the
Figure 5. HDAC6 inhibition counteracts promotion of tolerance
by lithium. A, Astrocytes were pretreated where indicated with
100 ng/mL LPS or no LPS (0) for 24 h and restimulated with 10 ng/mL
LPS for 1 h. HDAC6 was immunoprecipitated from cell lysates,
immunoprecipitants were immunoblotted for GSK3a, GSK3b,a n d
HDAC6, and GSK3 co-immunoprecipitation was quantified (n=3, mean
6 SEM, *p,0.05, Student’s t-test). B, Astrocytes were pretreated where
indicated with 100 ng/mL LPS or no LPS (0) and the GSK3 inhibitor
lithium (20 mM) with or without the HDAC6 inhibitor tubacin (10 mM)
for 24 h and restimulated with 10 ng/mL LPS for 24 h. Media were
analyzed for IL-6 by ELISA. Data represent mean 6 SEM, *p,0.05,
ANOVA. C, Mouse primary astrocytes were pretreated where indicated
with 100 ng/mL LPS or no LPS (0) and the GSK3 inhibitor lithium
(20 mM) with or without the HDAC6 inhibitor tubacin (10 mM) for 24 h
and restimulated with 10 ng/mL LPS for 1 h. Cell extracts were
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Following induction of semi-tolerance to LPS in astrocytes, we did
not observe an increase of anti-inflammatory cytokine production
[10] or a reduction in the surface expression of TLR4, but we
found decreases in the activation of both NF-kB and STAT3
[[10]; and data not shown]. Thus, mechanisms regulating
tolerance in astrocytes appear to differ from those exhibited by
peripheral immune cells.
This study found that the activity of the class IIb histone
deacetylase, HDAC6, is important for promoting LPS-tolerance of
IL-6 production in astrocytes, and that one mechanism by which
GSK3 counteracts LPS-tolerance is by inhibition of HDAC6.
These mechanisms indicate that inflammatory conditions in the
CNS associated with inhibition of HDAC6 or activation of GSK3
can impede the development of LPS-tolerance, which may
heighten deleterious pathological outcomes to inflammation.
Identification of a role for HDAC6 in promoting inflammatory
tolerance in astrocytes does not affect the likelihood that other
HDACs are also capable of modulating the development of
inflammatory tolerance in astrocytes as occurs in peripheral
immune cells [11,38]. This is evident from the capacity of valproic
acid, which inhibits HDACs other than HDAC6 and HDAC10, to
partially impede the development of semi-tolerance in astrocytes
(Fig. 3). However, identification of a regulatory role for HDAC6 in
tolerance fits well with previous evidence that HDAC6 has a
suppressive effect on MyD88-dependent signaling by TLRs [39].
Thus, the present results extend the known functions of HDAC6
in immune cells to also promote LPS-tolerance in astrocytes.
Although total cellular HDAC6 activity was not increased during
LPS tolerance, we observed a significant reduction of the
acetylation of a-tubulin during LPS-tolerance, indicative of
increased HDAC6 action in a subcellular compartment associated
with tubulin, and greatly increased tubulin acetylation after
treatment with the HDAC6 inhibitor tubacin, which also blocked
LPS-tolerance. These findings are consistent with a previous study
showing that HDAC6 deacetylase activity links the tubulin
cytoskeleton with immune synapse organization, whereas overex-
pression of HDAC6 greatly impaired the production of IL-2 [40].
The blockade of LPS-tolerance in IL-6 production was also
observed in microglia treated with tubacin, suggesting a more
generalized role of HDAC6 during LPS tolerance of IL-6
production. However, the precise mechanism by which HDAC6
promotes tolerance remains to be identified, which may involve its
regulation of acetyl-tubulin or other acetylated proteins. Since
HDAC6 has multiple cellular substrates, it is unknown which of
these mediates its promotion of tolerance, but a potential
mechanism is that regulation of acetyl-tubulin by HDAC6 alters
intracellular transport and signaling mechanisms, including
disruption of cytokine release.
The regulation of LPS tolerance by HDAC6 was also found to
be linked to the previously identified role of GSK3 in
counteracting LPS-tolerance [10]. Upon inhibition of HDAC6
with tubacin, as well as with TSA and sodium butyrate treatments,
there was a complete block of the promotion of tolerance by
lithium, which we previously demonstrated was due to its
inhibition of GSK3 [10], whereas inhibition of GSK3 promoted
HDAC6 activity and LPS-tolerance. Thus, these findings reveal
opposing actions of HDAC6 and GSK3 in regulating LPS-
tolerance, as HDAC6 promotes tolerance whereas GSK3
counteracts tolerance. A similar opposing action has been
described in other systems, where HDAC6 blocks phosphorylation
of b-catenin, whereas GSK3 phosphorylates b-catenin to promote
its degradation [13]. Moreover, an indirect action of HDAC6 on
GSK3 activity may be mediated by HDAC6 binding to the
catalytic subunit of protein phosphatase-1 (PP1) [41] which
promotes PP1 activity, which would lead ultimately to activation
of GSK3 [42] to impede LPS tolerance. In contrast, another study
found that HDAC6 is required for GSK3 phosphorylation of the
microtubule-associated protein tau [14]. These findings suggest
multiple regulatory interactions between HDAC6 and GSK3,
including potential direct interactions that is indicated by their co-
immunoprecipitation (Fig. 5A), that have context-specific func-
tional outcomes on the actions of HDAC6 and GSK3.
In summary, this study reports a new mechanism of regulation
of LPS-tolerance in astrocytes by the opposing actions of GSK3
and HDAC6. Thus, GSK3 inhibitors can promote LPS-tolerance,
whereas inhibition of HDAC6 counteracts LPS-tolerance. There-
fore, treatments that shift the balance between these two opposing
forces on inflammatory tolerance can obliterate or enhance
tolerance to LPS in astrocytes.
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